Therapix Biosciences Ltd (TRPX) - Financial and Strategic SWOT Analysis Review

January 2021 | 36 pages | ID: T243030CFB5EN
GlobalData

Abstracts

Therapix Biosciences Ltd (TRPX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Therapix Biosciences Ltd (Therapix), formerly Nasvax Ltd is a clinical stage biopharmaceutical company that focuses on the development of cannabinoid based pharmaceuticals for the treatment of central nervous system disorders. Therapix’s major product candidates include THX-130, for the treatment of mild cognitive impairment and traumatic brain injury; THX-110, for the treatment of tourette syndrome, obstructive sleep apnea and chronic pain; THX-150, for the treatment of antibacterial; and THX-160, for the treatment of pain. The company conducts its clinical programs in collaboration with various pharma companies and institutions. Therapix Biosciences is headquartered in Tel Aviv, Israel.

Therapix Biosciences Ltd Key Recent Developments

Aug 21,2020: Therapix Biosciences announces replacement of its Board of Directors
Jul 01,2020: Therapix Biosciences receives Notice of Delisting and Injunction from Israeli Court
May 07,2020: Therapix Biosciences appoints Prof. Ari Shamiss (M.D., M.P.A.) to the company's board of directors
Apr 22,2020: Therapix Biosciences announces appointment of new CEO

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

Table of Contents
List of Tables
List of Figures

SECTION 1 - ABOUT THE COMPANY

Therapix Biosciences Ltd - Key Facts
Therapix Biosciences Ltd - Key Employees
Therapix Biosciences Ltd - Key Employee Biographies
Therapix Biosciences Ltd - Major Products and Services
Therapix Biosciences Ltd - History
Therapix Biosciences Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Therapix Biosciences Ltd - Business Description
Therapix Biosciences Ltd - SWOT Analysis
SWOT Analysis - Overview
Therapix Biosciences Ltd - Strengths
Therapix Biosciences Ltd - Weaknesses
Therapix Biosciences Ltd - Opportunities
Therapix Biosciences Ltd - Threats
Therapix Biosciences Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Therapix Biosciences Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 21, 2020: Therapix Biosciences announces replacement of its Board of Directors
Jul 01, 2020: Therapix Biosciences receives Notice of Delisting and Injunction from Israeli Court
May 07, 2020: Therapix Biosciences appoints Prof. Ari Shamiss (M.D., M.P.A.) to the company's board of directors
Apr 22, 2020: Therapix Biosciences announces appointment of new CEO

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Therapix Biosciences Ltd, Key Facts
Therapix Biosciences Ltd, Key Employees
Therapix Biosciences Ltd, Key Employee Biographies
Therapix Biosciences Ltd, Major Products and Services
Therapix Biosciences Ltd, History
Therapix Biosciences Ltd, Subsidiaries
Therapix Biosciences Ltd, Key Competitors
Therapix Biosciences Ltd, Ratios based on current share price
Therapix Biosciences Ltd, Annual Ratios
Therapix Biosciences Ltd, Annual Ratios (Cont...1)
Therapix Biosciences Ltd, Interim Ratios
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Therapix Biosciences Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Therapix Biosciences Ltd, Performance Chart (2015 - 2019)
Therapix Biosciences Ltd, Ratio Charts
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

COMPANIES MENTIONED

Bio-Cell Ltd
BiondVax Pharmaceuticals Ltd
Compugen Ltd
Neopharm Ltd
Rafa Laboratories Co Ltd